Ipamorelin
Also known as: NNC 26-0161
Ipamorelin is a synthetic growth hormone secretagogue (a ghrelin-mimetic) studied in early research for its reported ability to stimulate growth hormone release. It is not approved for human use in Australia.
- Category
- Growth Hormone Secretagogue
- Reported half-life
- Reported ~2 hours (varies by study)
- Common forms
- Lyophilised powder for reconstitution, Injectable solution
- Research status
- Not approved for human use in Australia; investigated in early clinical and preclinical research only. No marketed human therapeutic product.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to stimulate a pulse of growth hormone release
- Claimed by users to support recovery, body composition and sleep quality
- Early research indicates a relatively selective effect with limited impact on cortisol or prolactin in some studies
- Reported appetite effects via ghrelin-receptor activity
How it is reported to work
Ipamorelin is reported to mimic ghrelin and act on the growth hormone secretagogue receptor, prompting the pituitary gland to release a pulse of growth hormone. It is described in early research as relatively selective, meaning it is reported to raise growth hormone with comparatively little effect on other hormones such as cortisol. These findings come from early and animal research and are not established in large human trials.
Background
Ipamorelin is a synthetic growth hormone secretagogue - a compound reported to mimic the hormone ghrelin and prompt the release of growth hormone from the pituitary gland. It is often discussed alongside CJC-1295 in online communities interested in recovery and body composition. This page is educational information, not medical advice, and the effects below are claimed and reported rather than medically established.
What the research actually shows
Ipamorelin has been examined in early-stage and animal research, where it is reported to trigger a pulse of growth hormone release with relatively selective effects on other hormones. However, large, long-term human clinical trials confirming benefits and safety are not available. Promising early data does not equal proven outcomes.
| Evidence type | Status |
|---|---|
| Early/animal research | Present |
| Large human trials | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, people report using ipamorelin in attempts to support recovery, sleep quality and body composition. These are anecdotal reports, not validated clinical results. Studies suggest the mechanism involves the growth hormone secretagogue receptor, but reported benefits should not be read as established facts.
Things to be aware of
Ipamorelin is not approved for human use in Australia. Manipulating growth hormone pathways can have unintended effects, and the long-term consequences are not well characterised in humans. Grey-market product purity cannot be verified by sight, which is why independent testing is a topic in this community.
If you have a health or recovery concern, the appropriate step is to talk to a qualified healthcare professional rather than self-experimenting. This article exists to help readers understand ipamorelin and the surrounding evidence; it is not an endorsement and does not recommend obtaining or using it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to stimulate a natural pulse of the body's own growth hormone
- Users report improved sleep quality and deeper sleep
- Reported to support recovery and body composition over time
- Reported to be relatively selective, with comparatively little effect on cortisol or prolactin
- Reported milder appetite stimulation than stronger ghrelin-mimetics
Common side effects
- Injection-site irritation, redness or itching
- Head-rush, flushing or warmth shortly after injection
- Increased appetite or hunger in some users
- Water retention or tingling in hands reported anecdotally
- Drowsiness, especially with evening dosing
Rare / serious side effects
- Numbness or carpal-tunnel-like symptoms reported with sustained growth-hormone elevation
- Changes in blood-sugar handling or insulin sensitivity
- Allergic-type reactions
- Reactions attributed to impurities in unregulated grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Ipamorelin. Listed so you can make an informed decision, not to suggest any use is safe.
- Chronic high-dose use is reported to risk down-regulating the body's own growth-hormone pulses, a suppression concern that can blunt natural production over time
- Sustained elevation of growth hormone and IGF-1 from overuse is reported to risk insulin resistance and higher blood sugar
- Overuse is reported to risk fluid retention, joint aches and carpal-tunnel-type symptoms, mirroring growth-hormone excess
- Because IGF-1 promotes cell growth, prolonged overuse raises a frequently cited theoretical concern about feeding abnormal tissue growth
- Unverified grey-market product is reported to risk contamination and incorrect dosing
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Sleep improvements are often reported within days, while body-composition and recovery changes are reported to build over several months.
First effects
Improved sleep within days
Noticeable change
Recovery and well-being ~4 weeks
Clear results
Body-composition changes ~12 weeks
Peak effect
Fuller effects reported ~16-24 weeks
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Ipamorelin. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Reported community figures of roughly 200–300 mcg per dose (often run with CJC-1295) |
| Frequency | Reported as 1–3× daily (commonly before bed and/or before training) |
| Cycle length | Reported cycles of about 8–12 weeks, then a break |
Reported reconstitution (mg → units)
Worked example only: a 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 200 mcg (0.2 mg) dose ≈ 0.08 mL = 8 units on a U-100 insulin syringe; a 300 mcg (0.3 mg) dose ≈ 0.12 mL = 12 units.
Work out the units for your vial → CalculatorCommonly reported community patterns describe daily injections, often at night and/or before training, run in cycles of roughly 8 to 12 weeks followed by a break, frequently paired with a GHRH analogue such as CJC-1295. These are reported patterns only, not a recommendation, and ipamorelin is not approved for human use.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Very commonly reported together, with users reporting that a GHRH analogue plus a ghrelin-mimetic amplifies the growth-hormone pulse
Reported alongside for recovery and injury support
Reported in growth-hormone-focused stacks aimed at body composition
Safety notes
Ipamorelin is not approved by the TGA for human use in Australia, and long-term human safety data is lacking. Stimulating growth hormone pathways can carry risks, and grey-market product purity cannot be verified by consumers. Anyone considering it should first consult a qualified healthcare professional.